REFERENCES

1. Kurman RJ, Shih I-M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34:433-43.

2. Goff B. Symptoms associated with ovarian cancer.

3. Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA 2011;305:2295-303.

4. Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 2016;387:945-56.

5. Jacobs I, Oram D, Fairbanks J, et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97:922-29.

6. Dayyani F, Uhlig S, Colson B, et al. Diagnostic performance of risk of ovarian malignancy algorithm against CA125 and HE4 in con­nection with ovarian cancer: a meta-analysis. Int J Gynecol Cancer 2016;26:1586-93.

7. Prat J, FIGO Committee on Gynecologic Oncology. Staging clas­sification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014;124:1-5.

8. Nasser S, Lazaridis A, Evangelou M, et al. Correlation of pre­operative CT findings with surgical & histological tumor dis­semination patterns at cytoreduction for primary advanced and relapsed epithelial ovarian cancer: a retrospective evaluation. Gynecol Oncol 2016;143:264-69.

9. Fehniger J, Thomas S, Lengyel E, et al. A prospective study evalu­ating diffusion weighted magnetic resonance imaging (DW-MRI) in the detection of peritoneal carcinomatosis in suspected gyne­cologic malignancies. Gynecol Oncol 2016;142:169-75.

10. Mapelli P, Incerti E, Fallanca F, et al. Imaging biomarkers in ovarian cancer: the role of 18F-FDG PET/CT.

11. Garcia-Soto AE, Boren T, Wingo SN, et al. Is comprehensive surgical staging needed for thorough evaluation of early-stage ovarian carcinoma? Am J Obstet Gynecol 2012;206:242.e1-5.

12. Maggioni A, Benedetti Panici P, Dell'Anna T, et al. Randomised study of systematic lymphadenectomy in patients with epithelial

13. Fruscio R, Corso S, Ceppi L, et al. Conservative management of early-stage epithelial ovarian cancer: results of a large retro­spective series. Ann Oncol 2013;24:138-44.

14. Ditto A, Martinelli F, Reato C, et al. Systematic para-aortic and pelvic Jymphadenectomy in early stage epithelial ovarian cancer: a prospective study. Ann Surg Oncol 2012;19:3849-55.

15. Suzuki M, Ohwada M, Yamada T, et al. Lymph node metastasis in stage I epithelial ovarian cancer. Gynecol Oncol 2000;79:305-308.

16. du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical out­come as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 2009;115:1234-44.

17. van der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prog­nosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332:629-34.

18. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943-53.

19. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet 2014;384:1376-88.

20. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian car­cinoma during the platinum era: a meta-analysis.

21. Harter P, Sehouli J, Lorusso D, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med 2019;380(9):822-32.

22. Aletti GD, Gostout BS, Podratz KC, Cliby WA. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol 2006;100:33-37.

23. Rose PG, Nerenstone S, Brady MF, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004;351:2489-97.

24. Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-l abel, randomised, controlled, non-infer- iority trial. Lancet 2015;386:249-57.

25. Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003;95:105-12.

26. Collinson F, Qian W, Fossati R, et al. Optimal treatment of early- stage ovarian cancer. Ann Oncol 2014;25:1165-71.

27. Trimbos B, Timmers P, Pecorelli S, et al. Surgical staging and treat­ment of early ovarian cancer: long-term analysis from a random­ized trial. J Natl Cancer Inst 2010;102:982-87.

28. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.

29. Pignata S, Scambia G, Ferrandina G, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxo­rubicin as first-line treatment for patients with ovarian cancer: the MITO- 2 randomized phase III trial. JClin Oncol 2011;29:3628-35.

30. Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose- dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallo­pian tube, or primary peritoneal cancer (JGOG 3016): a random­ised, controlled, open-label trial.

31. Chan JK, Brady MF, Penson RT, et al. Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med 2016;374:738-48.

32. Pignata S, Scambia G, Katsaros D, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2014;15:396-405.

33. Clamp A, McNeish I, Dean A, et al. ICON8: a GCIG phase III ran­domised trial evaluating weekly dose-dense chemotherapy integra­tion in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: results ofprimary progression-free sur­vival (PFS) analysis. Ann Oncol 2017;28(Suppl. 5):abstract 929O_PR.

34. Naumov GN, Bender E, Zurakowski D, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 2006;98:316-25.

35. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473-83.

36. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl JMed 2011;365:2484-96.

37. Oza A, Perren T, Swart A, et al. ICON7: final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. Abstract 6. Presented at: European Society of Medical Oncology Annual Meeting; Amsterdam, The Netherlands, 30 September 2013.

38. Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018 Oct 21;379(26):2495-505.

39. Trimble EL, Thompson S, Christian MC, Minasian L. Intraperitoneal chemotherapy for women with epithelial ovarian cancer. Oncologist 2008;13:403-409.

40. Tewari D, Java JJ, Salani R, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study.

41. Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, DiSilvestro PA, et al. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol 2019 Jun 1;37(16):1380-90.

42. Harter P, du Bois A, Mahner S, et al. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Geburtshilfe Frauenheilkd 2016;76:147-49.

43. Diaz-Padilla I, Malpica AL, Minig L, et al. Ovarian low-grade serous carcinoma: a comprehensive update. Gynecol Oncol 2012;126:279-85.

44. Grabowski JP, Harter P, Heitz F, et al. Operability and chemo­therapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecol Oncol 2016;140:457-62.

45. Gershenson DM, Sun CC, Bodurka D, et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 2009;114:48-52.

46. Gershenson DM, Sun CC, Iyer RB, et al. Hormonal therapy for re­current low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 2012;125:661-66.

47. Grisham RN, Iyer G, Sala E, et al. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer. Int J Gynecol Cancer 2014;24:1010-14.

48. Farley J, Brady WE, Vathipadiekal V, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peri­toneum: an open-label, single-arm, phase 2 study. Lancet Oncol 2013;14:134-40.

49. Chan JK, Teoh D, Hu JM, et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 2008;109:370-76.

50. Tan DSP, Kaye S. Ovarian clear cell adenocarcinoma: a continuing enigma. J Clin Pathol 2007;60:355-60.

51. Sugiyama T, Okamoto A, Enomoto T, et al.

52. Friedlander ML, Russell K, Millis S, et al. Molecular profiling of clear cell ovarian cancers: identifying potential treatment targets for clinical trials. Int J Gynecol Cancer 2016;26:648-54.

53. Ledermann JA, Luvero D, Shafer A, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian car­cinoma. Int J Gynecol Cancer 2014;24:S14-19.

54. Vergote I, Rustin GJ, Eisenhauer EA, et al. Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). Gynecologic Cancer Intergroup. J Natl Cancer Inst 2000;92:1534-35.

55. Rustin GJS, van der Burg MEL, Griffin CL, et al. Early versus de­layed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010;376:1155-63.

56. Harter P, Hahmann M, Lueck HJ, et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical impli­cations, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol 2009;16:1324-30.

57. Harter P, Sehouli J, Reuss A, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 2011;21:289-95.

58. Friedlander M, Trimble E, Tinker A, et al. Clinical trials in recur­rent ovarian cancer. Int J Gynecol Cancer 2011;21:771-75.

59. Raja F, Counsel N, Colombo N, et al. Platinum combination chemotherapy versus platinum monotherapy in platinum-sensi­tive recurrent ovarian cancer: a meta-analysis of randomised trials using individual patients data (IPD). Ann Oncol 2012;23:982P.

60. Aghajanian C, Goff B, Nycum LR, et al. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive re­current ovarian cancer. Gynecol Oncol 2015;139:10-16.

61. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30:2039-45.

62. Coleman R, Brady M, Herzog T, et al. A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213). Gynecol Oncol 2015; 137 Suppl 1:3-4.

63. Pujade Lauraine E, Hilpert F, Weber B, et al. AURELIA: a ran­domized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 2012;30:LBA5002.

64. Stockler MR, Hilpert F, Friedlander M, et al. Patient-reported out­come results from the open-label phase III AURELIA trial evalu­ating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol 2014;32:1309-16.

65. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.

66. Moschetta M, George A, Kaye SB, Banerjee S. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann Oncol 2016;27:1449-55.

67. Ramus SJ, Gayther SA. The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol 2009;3:138-50.

68. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:1382-92.

69. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014;15:852-61.

70. Ledermann JA, Harter P, Gourley C, et al. Overall survival in pa­tients with platinum-sensitive recurrent serous ovarian cancer re­ceiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol 2016;17:1579-89.

71. Mirza MR, Pignata S, Ledermann JA. Latest clinical evidence and further development of PARP inhibitors in ovarian cancer. Ann Oncol. 2018 Jun 1;29(6):1366-76.

72. Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012;30:2654-63.

73. Liu JF, Barry WT, Birrer M, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent plat- inum-s ensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 2014; 15:1207-14.